Evidence Analysis

It is a challenge for health plans and clinicians to distill and analyze volumes of clinical evidence to determine likely clinical, financial, and risk impacts. This is what we do.

Accessed through the Hayes Knowledge Center, the Evidence Analysis Solution addresses the following fundamental questions to help our clients determine coverage positions:

  • Does the technology improve health outcomes?
  • Are there other benefits associated with the technology?
  • What harms might be associated with the technology?
  • Have patient selection criteria been established for the technology?
  • For which patients might the technology provide a benefit?

Use of Anti-infliximab Antibody Levels to Monitor Infliximab Treatment in Patients With Crohn Disease

Focus of the Report: This Health Technology Assessment focuses on anti-infliximab (IFX) antibody (ATI) testing in patients who are undergoing IFX treatment for Crohn disease (CD). This testing is a type of therapeutic drug monitoring (TDM) that is performed to help determine whether ongoing treatment is safe and effective and whether changes …

read more

Percutaneous Pulmonary Valve Implantation with the Edwards Sapien 3 and Sapien XT Valves (Edwards Lifesciences Corp.) for Right Ventricular Outflow Tract Defects

Focus of the Report: This Health Technology Assessment focuses on percutaneous pulmonary valve implantation (PPVI) with Edwards Sapien 3 or Sapien XT valves for the treatment of right ventricular outflow tract (RVOT) defects.

Technology Description: The goal of PPVI is to improve hemodynamics, cardiopulmonary function, and survival while delaying the n…

read more